Targeting the bacterial cell wall recycling to fight Pseudomonas infections
Official title: Intervention of Peptidoglycan Synthesis
Funded at University of Notre Dame · NIH-11338213 · Data updated 2026-11-12
Aims to block how the bacteria recycle its wall materials in Pseudomonas aeruginosa to help restore effectiveness of common antibiotics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $709,532 |
| NIH project number | 1R01AI198251-01 |
| Project ID | NIH-11338213 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with chronic Pseudomonas aeruginosa infections, especially those with cystic fibrosis, may benefit if new combination therapies become available.
✕Less likely to help
Direct benefits to patients may not occur unless the proposed compounds prove effective and safe in later trials.
What this research studies
This project looks at how Pseudomonas aeruginosa recycles peptidoglycan, a key component of its cell wall, and explores ways to block both the de novo and recycling pathways. By using a fluorescent probe to signal antibiotic resistance, researchers will screen compounds that could separate this resistance from the action of beta-lactam drugs. The goal is to find agents that make existing antibiotics work again against tough lung infections, including those in cystic fibrosis patients. The work combines basic biology with screening approaches that could translate into new combination therapies for patients.
Why it matters
Potential benefit: If successful, the approach could restore the effectiveness of antibiotics against hard-to-treat P. aeruginosa infections.
How similar studies have gone: Similar strategies have shown promise in restoring antibiotic effectiveness in bacteria, but this project is at an early discovery stage.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Mobashery, Shahriar — University of Notre Dame
- Study coordinator: Mobashery, Shahriar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.